ESTUDIO DE FASE 3, ALEATORIZADO, CONTROLADO CON PLACEBO, DE 52 SEMANAS DE DURACIÓN, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE SELADELPAR EN SUJETOS CON COLANGITIS BILIAR PRIMARIA (CBP) Y UNA RESPUESTA INSUFICIENTE O INTOLERANCIA AL ÁCIDO URSODESOXICÓLICO (AUDC).
Datos básicos
- Código:
- CB8025-31735
- Protocolo:
- CB8025-31735
- EUDRACT:
- 2018-001171-20
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2019
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
"Posttransplant calcineurin inhibitors levels and intra-patient variability are not associated with long term outcomes following liver transplantation".
Di Maira T; (...); Berenguer M
Article. 10.1097/TP.0000000000002987. 2020
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
Carvalho-Gomes Â; (...); Berenguer M
Article. 10.1371/journal.pone.0228351. 2020
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives.
Gitto S; (...); Berenguer M
Editorial Material. 10.1155/2019/8691502. 2019
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
ATP7B AND OTHER GENES RESULTING IN WILSON DISEASE (WD) PHENOTYPE
Sanchez-Monteagudo, A; (...); Berenguer, M
Meeting Abstract. 2019
Baseline features of hepatitis C patients associated to prescription of pangenotypic antiviral treatments: results from the real-world Spanish Hepa-C registry
Turnes, Juan; (...); Perez Cachafeiro, Santiago
Meeting Abstract. 2020
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
CLINICAL PRESENTATION AND OUTCOMES OF DE NOVO HEPATITIS B VIRUS INFECTION AFTER LIVER TRANSPLANTATION IN SPAIN.
Pascasio Acevedo, Juan Manuel; (...); Manuel Sousa, Jose
Meeting Abstract. 2019
Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients
Reig, Anna; (...); Pares, Albert
Meeting Abstract. 2020
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).
Rodríguez M; (...); García-Samaniego J
Article. 10.1016/j.gastrohep.2020.03.011. 2020
Corrigendum to "Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives".
Gitt S; (...); Berenguer M
Correction. 10.1155/2020/4305190. 2020
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
COVID-19 and liver transplantation
Editorial Material. 10.1038/s41575-020-0347-z. 2020
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain
Hernandez-Evole, H, Briz-Redon, A, Berenguer, M
Article. 10.4254/wjh.v12.i6.277. 2020
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.
Chen Q; (...); Quer J
Article. 10.1016/j.antiviral.2019.104694. 2020
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting
Perricone, G; (...); European Liver Intestine Transpla
Article. 10.1111/liv.13878. 2018
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis.
Ampuero J; (...); Del Pozo Maroto E
Article. 10.1016/j.cgh.2019.05.051. 2020
Digital pathology: accurate technique for quantitative assessment of histological features in metabolic-associated fatty liver disease
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1111/apt.16100. 2021
Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study (vol 18, pg 2513, 2018)
Manzardo, C.; (...); Samuel, D.
Correction. 10.1111/ajt.15244. 2019
Distinct features of hepatitis delta in a Mediterranean setting
Hernandez-Evole, H, Berenguer-Haym, M
Meeting Abstract. 10.1016/S0618-8278(19)30486-4. 2019
Does Surgeon Fatigue Influence the Results of Liver Transplantation?
Bosca, A; (...); Lopez-Andujar, R
Article. 10.1016/j.transproceed.2018.03.139. 2019
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry
Turnes, Juan; (...); Perez Cachafeiro, Santiago
Meeting Abstract. 2020
Effectiveness, safety/tolerability of OBV/PTV/r DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Londoño MC; (...); García-Buey L
Article. 10.1371/journal.pone.0221567. 2019
Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)
Puigvehi, M; (...); Carrion, JA
Meeting Abstract. 10.1016/S0618-8278(19)30399-8. 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
Crespo, J; (...); Antolin, GS
Article. 10.17235/reed.2019.6700/2019. 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).
Crespo J; (...); Sánchez Antolín G
Article. 10.1016/j.gastrohep.2019.09.002. 2019
Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients.
Colmenero J; (...); Pons JA
Article. 10.1016/j.jhep.2020.07.040. 2021
Equally Interchangeable? How Sex and Gender Affect Transplantation
Melk, A; (...); Berenguer, M
Review. 10.1097/TP.0000000000002655. 2019
Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
Ampuero J; (...); Romero-Gómez M
Correction. 10.1016/j.jhep.2020.06.018. 2020
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fat, cancer, the gut-liver axis and rare liver diseases.
Editorial Material. 10.1016/j.jhepr.2020.100189. 2020
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Genetics of Wilson disease and Wilson-like phenotype in a clinical series from eastern Spain.
Sánchez-Monteagudo A; (...); Espinós C
Article. 10.1111/cge.13719. 2020
Heat stroke and fulminant hepatitis: Conservative management or liver transplant?
Ladrón Abia P; (...); Berenguer Haym MC
Letter. 10.1016/j.gastrohep.2020.11.004. 2021
Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients
Suarez, E; (...); Simon, MA
Article. 10.1097/MEG.0000000000001289. 2019
Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19
Del Hoyo, J.; (...); Aguilera, V
Editorial Material. 2020
Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
Del Hoyo J; (...); Aguilera V
Editorial Material. 10.1111/jgh.15174. 2020
HIV infection is not associated with increased cardiovascular (CV) risk in liver transplant (LT) recipients: a single centre comparative study
Vinaixa, C.; (...); Prieto, M.
Meeting Abstract. 2019
Immunosuppression in liver transplant.
Di Maira T, Little EC, Berenguer M
Review. 10.1016/j.bpg.2020.101681. 2020
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation
Tsochatzis, E; (...); Berenguer, M
Review. 10.1097/TP.0000000000002433. 2019
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients (vol 102, pg 727, 2018)
Correction. 10.1097/TP.0000000000002535. 2019
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients
Rodriguez-Tajes, Sergio; (...); Forns, Xavier
Meeting Abstract. 2020
Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion.
Schneider S; (...); Berenguer M
Article. 10.1111/ctr.13629. 2019
Long-term patient and graft survival after liver transplantation for autoimmune hepatitis
Heinemann, Melina; (...); Schramm, Christoph
Meeting Abstract. 2020
Long-term survival after liver transplantation for autoimmune hepatitis - results from the European Liver Transplant Registry.
Heinemann M; (...); Schramm C
Article. 10.1002/lt.25739. 2020
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation.
Herreras J; (...); Berenguer M
Article. 10.1097/TXD.0000000000000934. 2019
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
MORE THAN A THIRD OF UNTREATED PATIENTS WITH CHRONIC HEPATITIS DELTA HAVE A DECREASE OR REACH UNDETECTABLE LEVELS OF HDV-RNA DURING NATURAL HISTORY
Palom, A; (...); Ferret, MAB
Meeting Abstract. 2020
Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital
Bejar-Serrano, S; (...); Benlloch, S
Article. 10.1016/j.gastrohep.2018.07.017. 2019
Out-of-Milan HCC criteria and worse intention-to-treat results following liver transplantation
Herreras, J.; (...); Berenguer, M.
Meeting Abstract. 2019
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Periesophageal Lymph Node Metastasis of Prostate Adenocarcinoma From Liver Transplant Donor
Sanchez-Montes, C; (...); Arguello, L
Editorial Material. 10.14309/ajg.0000000000000135. 2019
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
PHYSICAL FRAILTY IN LIVER TRANSPLANTATION.
Puchades Renau L; (...); Berenguer Haym M
Review. 10.17235/reed.2020.7448/2020. 2021
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference
Berenguer, M; (...); van der Laan, LJW
Review. 10.1097/TP.0000000000003196. 2020
Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; (...); Berenguer M
Article. 10.1016/j.aohep.2019.06.014. 2019
Predictive factors of response to corticosteroid therapy in acute severe autoinmune hepatitis: a national multicentric study
Sanchez Rodriguez, Eugenia; (...); Albillos, Agustin
Meeting Abstract. 2020
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis.
Llovet LP; (...); Londoño MC
Letter. 10.1016/j.cgh.2018.12.030. 2019
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
Gordon, CE; (...); Martin, P
Article. 10.7326/M19-1539. 2019
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Proceedings of the 25th Annual Congress of the International Liver Transplantation Society.
Chadha R; (...); Bhangui P
Review. 10.1097/TP.0000000000003160. 2020
Re: Tacrolimus Trough Concentrations after Liver Transplantation: .
Di Maira T; (...); Berenguer M
Letter. 10.1097/TP.0000000000003087. 2020
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Manuel Sousa J; (...); Manzanares A
Article. 10.1371/journal.pone.0225061. 2019
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Selective Indication of T-Tube in Liver Transplantation: Prospective Validation of the Results of a Randomized Controlled Trial
Lopez-Andujar, R; (...); Montalva, EM
Article. 10.1016/j.transproceed.2018.03.133. 2019
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Ampuero, J; (...); Gomez, MR
Article. 10.1016/j.jhep.2020.02.028. 2020
Temporal Trends and Outcomes in Liver Transplantation for Recipients with Human Immunodeficiency Virus Infection in Europe and United States.
Campos-Varela I; (...); Terrault NA
Article. 10.1097/TP.0000000000003107. 2019
The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD
Ampuero, J; (...); Gomez, MR
Meeting Abstract. 10.1016/S0618-8278(19)30234-8. 2019
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Ampuero, J; (...); HEPAmet Registry
Article. 10.1111/apt.15015. 2018
The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage
Burra, P, Berenguer, M, Pomfret, E
Article. 10.1097/TP.0000000000002507. 2019
THE IMPACT OF DIRECT ACTING ANTIVIRALS ON HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC RETROSPECTIVE STUDY
Gorgen, A; (...); Sapisochin, G
Meeting Abstract. 2019
The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study
Gorgen, A; (...); Sapisochin, G
Article. 10.1097/TP.0000000000003115. 2020
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Transplant Oncology in Primary and Metastatic Liver Tumor: Principles, Evidence and Opportunities.
Sapisochin G; (...); Mazzaferro V
Article. 10.1097/SLA.0000000000004071. 2020
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection
Cabezas, J; (...); Crespo, J
Meeting Abstract. 10.1016/S0618-8278(19)30970-3. 2019
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Very early immunosuppression predicts the first-year renal function post liver transplantation
Di Maira, T.; (...); Berenguer, M.
Meeting Abstract. 2019
Wide variations in liver transplantation (LT) policies across Europe for patients with acute-on-chronic liver failure (ACLF) despite excellent post-LT survival: Results of a CLIF/ELITA collaborative study
Belli, Luca Saverio; (...); Arroyo, Vicente
Meeting Abstract. 2020